TRESIBA® – summary of benefits
for patients with type 2 diabetes
Reduction in HbA1c
vs glargine U1001,2
Can significantly increase
Time in Range vs glargine U10019
Flat and stable, with duration
of action beyond 42 hours12,13
To help reassure patients
of few hypos1-3,26*
* Compared with glargine U100 or glargine U300.1-3,26
© Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark.
HQ21TSM00031 Approval date: March 2022.